News | August 22, 2022
8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
